ABSMR Corporate Advisory Board

The ASBMR Corporate Advisory Board (CAB) was established by ASBMR to bring together an elite group of the Society’s corporate partners to meet in an informal, collegial environment with ASBMR’s executive leadership. By pooling resources and expertise, the CAB engages in joint problem solving and collaborative opportunities that focus on how we can deepen our understanding of each other as well as meet our mutual goals of advancing the bone, mineral and musculoskeletal field.

Membership in the 2025 ASBMR Corporate Advisory Board is $25,000 

Benefits

Knowledge Sharing: The CAB is about establishing meaningful dialogue and problem solving between industry and thought leaders in bone, mineral and musculoskeletal health, including rare bone diseases, and includes ASBMR’s Executive Committee – to develop new products and services to advance the field forward.


Partnership:  Corporate Advisory Board members will be able work alongside ASBMR’s leadership, discuss the field’s issues of mutual concern, pressing challenges, share knowledge on best practices and partner with ASBMR on major initiatives, and to improve quality outcomes including the continuation of the Working Group for Transition to Care in Rare Bone Diseases.


Advocacy: Stay informed on our work and coverage of CMS, FLS and DEXA initiatives for various bone diseases, including national advocacy against proposed changes to policies and decreased funding for research and on-going advocacy in relation to reimbursement.

Networking: CAB members will have access to ASBMR leadership in intimate, collegial settings to allow for direct connections with bone, mineral and musculoskeletal thought leaders.

Recognition: ASBMR will recognize CAB members in a variety of ways throughout the year among the Society’s global membership of clinical, research and industry experts, and in conjunction with the Annual Meeting including logo and/or company acknowledgement in ASBMR’s Annual Supporter and Exhibitor Kit, on signage, e-Blasts, slides, and mobile app.

 

Additionally, each member company will receive:

  • One complimentary full registration to the ASBMR 2025 Annual Meeting
  • Representatives from companies include a scientist member as well as someone from a senior marketing and/or tradeshow position, advocacy relations role, and others
  • Participation in the spring (via Zoom) and summer (in-person) Corporate Advisory Board Meetings
  • The opportunity for networking with ASBMR’s leadership at the Annual VIP Recognition Reception held during the ASBMR 2025 Annual Meeting in Seattle, WA, USA
  • One-on-one leadership meetings with each CAB member companies
  • New – Updates three time a year on the status of ASBMR Strategic Priorities

The ASBMR gratefully acknowledges the following companies for their 2024 Corporate Advisory Board membership:


Alexion, AstraZeneca Rare Disease
Amgen
Ascendis Pharma A/S
Ipsen Biopharmaceuticals, Inc.
Kyowa Kirin, Inc.
Radius Health
Regeneron Pharmaceuticals, Inc.
Sandoz
Takeda
UCB
Ultragenyx



Please contact Deb Kroll via email at [email protected] with any questions you may have about joining the 2025 ASBMR Corporate Advisory Board.

*ASBMR Corporate Advisory Board dues count in total yearly corporate support for additional benefits.